Your session is about to expire
Levemir vs Novolog
Introduction
For patients with type 1 or type 2 diabetes, certain medications that help control blood sugar levels can prevent complications and manage symptoms. Levemir and Novolog are two such drugs that are frequently prescribed for diabetes management. Both of these diabetic medications have different onset times and durations but share the common goal of controlling high blood sugar levels. Levemir is a long-acting insulin analog used to maintain basal (background) insulin level throughout the day, meaning it's typically taken once or twice daily depending on individual needs. On the other hand, Novolog is a rapid-acting insulin analog designed to mimic your body’s natural mealtime insulin response; hence it's usually taken at meal times to control post-meal spikes in blood glucose levels.
Levemir vs Novolog Side By Side
| Attribute | Levemir | Novolog |
|---|---|---|
| Brand Name | Levemir | Novolog |
| Contraindications | Allergy to any ingredients of Levemir, episode of hypoglycemia | Allergy to any ingredients of Novolog, episode of hypoglycemia |
| Cost | Around $290 for a 10ml vial (100units/ml) | Around $300 for one vial (10ml, 100units/ml) |
| Generic Name | Insulin detemir | Insulin aspart |
| Most Serious Side Effect | Signs of allergic reaction, low potassium level, fluid retention, hypoglycemia, hyperglycemia | Signs of an allergic reaction, unusual changes in mood or behavior, symptoms of heart failure, severe pain in your upper stomach, low potassium level, vision problems |
| Severe Drug Interactions | Not specifically mentioned in the article, but interactions that affect blood glucose levels should be monitored | Not specifically mentioned in the article, but interactions that affect blood glucose levels should be monitored |
| Typical Dose | Varies, typically used once or twice daily | Administered within 5-10 minutes before a meal, dosage adjusted based on blood glucose readings |
What is Levemir?
Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin analog that was first approved by the FDA in 2005. It works by lowering levels of glucose (sugar) in the blood and is used for both type 1 and type 2 diabetes. Levemir provides a steady level of insulin over an extended period, effectively "trapping" it in the body for longer than usual to help control high blood sugar throughout the day.
On the other hand, Insulin aspart (the generic name for NovoLog) is a fast-acting insulin analog. Its onset of action is approximately 15 minutes, compared to several hours for Levemir. It's mainly used to control blood sugar levels during meals or snacks and immediately after meals. This means that while Levemir has less immediate effect on glucose levels but lasts longer, NovoLog has strong effects on these glucose levels but lasts only a short time - this results in it having slightly more potential side effects related to low blood sugar.
What conditions is Levemir approved to treat?
Levemir and Novolog are both approved for the treatment of diabetes, but they serve different roles:
- Levemir is a long-acting insulin analog used to control blood glucose levels in adults and children with type 1 diabetes and adults with type 2 diabetes.
- Novolog, on the other hand, is a rapid-acting insulin analog prescribed to improve glycemic control in adult and pediatric patients with diabetes mellitus. It's typically taken at mealtime or soon after starting a meal to prevent spikes in blood sugar levels that can result from eating.
How does Levemir help with these illnesses?
Levemir helps to manage diabetes by mimicking the function of insulin, a hormone that regulates the amount of glucose in the blood. It acts slowly and steadily, providing a consistent level of insulin over a 24-hour period. This long-acting property allows for once or twice daily dosing which aids in maintaining relatively stable blood glucose levels throughout the day and night. On the other hand, Novolog is a rapid-acting form of insulin designed to control post-meal or prandial sugar spikes. It begins working within minutes after injection, peaks at about one hour afterwards and continues to work for two to four hours. Unlike Levemir which provides basal coverage - background insulin needed regardless of meals taken - Novolog is used when fast-acting relief from high blood sugar surge due to meal intake is required.
What is Novolog?
NovoLog, also known as Insulin aspart, is a fast-acting insulin analog. It works by mimicking the body's natural insulin secretion in response to increased blood glucose levels after meals, meaning it helps regulate blood sugar quickly. NovoLog was first approved by the FDA in 2000.
Unlike Levemir which is long acting and maintains a steady level of insulin over time for baseline needs, Novolog rapidly reduces blood sugar spikes that occur when you eat. The faster onset of action allows it to be taken closer to mealtime (within 5-10 minutes before eating).
It's important to note that while Novolog provides improved post-meal glucose control compared with other rapid-acting insulins, this doesn't mean it should replace long-term treatment options such as Levemir for those who need basal insulin regulation. In fact, many patients may use both types together or switch between them based on doctor’s advice.
What conditions is Novolog approved to treat?
Novolog is an FDA-approved insulin analog for the treatment of both type 1 and type 2 diabetes. The key benefits of Novolog are:
- Rapid onset of action, typically beginning to work within 15 minutes
- Peak effect at approximately one hour post-injection
- Duration of activity lasting between three to five hours
These properties make it particularly useful as a mealtime insulin to help control blood sugar spikes that occur after meals.
How does Novolog help with these illnesses?
Insulin is a hormone that plays a crucial role in metabolism, and it allows the body to use glucose for energy or store it for future use. Novolog (insulin aspart) is an insulin analogue with a rapid onset of action which mimics the natural mealtime insulin surge in healthy individuals. It begins working more quickly than regular human insulin, typically within 10-20 minutes after injection, providing greater flexibility in timing your meals and injections relative to other long-acting insulins such as Levemir (insulin detemir). The quick action of Novolog helps control post-meal blood sugar spikes that can be particularly detrimental in people with diabetes. Its effects usually last between three and five hours. This characteristic makes it especially useful for controlling blood sugar levels during meals and preventing high sugar levels after eating, which are common challenges faced by patients with diabetes.
How effective are both Levemir and Novolog?
Both insulin detemir (Levemir) and insulin aspart (Novolog) are well-established in managing blood sugar levels for people with diabetes. They were both approved by the FDA within a few years of each other, Levemir in 2005 and Novolog in 2000. As they have different durations of action, they may be prescribed under different circumstances. Insulin detemir is a long-acting basal insulin that provides consistent glucose control for up to 24 hours, while insulin aspart is a rapid-acting insulin used to control post-mealtime blood sugar spikes.
The effectiveness of these two types of insulins was directly studied; they exhibited similar efficacy in managing overall glycemic control when combined with appropriate mealtime or bolus insulins but serve different roles due to their differing onset and duration profiles.
A review on insulin detemir indicated that it can provide predictable and sustained glycemic control making it an important tool for basal-bolus therapy regimens where fine-tuning glucose levels is necessary. It's also been observed that weight gain associated with its use might be less compared to other long-acting insulins.
Studies on the short acting nature of Insulin aspart indicate its usefulness at meal times where rapid absorption helps curtail sudden rises in blood sugars after eating. However, it should generally be used together with a longer-acting insulin for complete coverage throughout the day.
In conclusion, both medications play distinct yet complementary roles when used correctly within comprehensive diabetes management plans.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Levemir typically prescribed?
Dosing for Levemir (insulin detemir) can vary greatly among individuals, but it is typically used once or twice daily. The dosage may be adjusted based on blood glucose monitoring results and the individual's insulin needs. On the other hand, Novolog (insulin aspart) is a rapid-acting insulin often taken at meal times to control post-meal blood sugar spikes. The dose of Novolog should be calculated according to carbohydrate intake, pre-meal blood glucose level and individual sensitivity to insulin. In both cases, dosages must always be determined by a healthcare provider with expertise in managing diabetes due to potential risks associated with incorrect dosing.
At what dose is Novolog typically prescribed?
Novolog treatment is typically initiated based on the individual's blood sugar levels and physician guidance, often in conjunction with long-acting insulin or other diabetes drugs. The dosage can then be adjusted according to blood glucose readings and under your healthcare provider's direction. It is usually administered within 5-10 minutes before a meal, but sometimes may be used immediately after meals if needed. Novolog should not be used if blood sugars are low prior to meals (hypoglycemia). If the desired level of glucose control isn't achieved after several weeks of consistent use at maximum effectiveness, consult with your medical team for alternative treatment options or adjustments in dosing strategy.
What are the most common side effects for Levemir?
Common side effects of Levemir and Novolog can include:
- Hypoglycemia (low blood sugar) which may cause anxiety, nervousness, tremors, sweating, and confusion
- Injection site reactions such as pain or redness
- Weight gain
- Headache
- Upper respiratory tract infection symptoms like pharyngitis and sinusitis
- Flu-like syndrome including fever, chills, muscle aches
- Allergic reactions which might result in rash or itching
Remember that each individual's reaction to medication is unique. If you experience any discomforting symptoms while using Levemir or Novolog insulin injections for diabetes management, consult your healthcare provider immediately.
Are there any potential serious side effects for Levemir?
While Levemir and Novolog are both insulin medications used to manage diabetes, they can have different side effects. In rare cases, serious side effects can occur with both these drugs:
- Signs of allergic reaction: hives; difficulty breathing; swelling in your face or throat
- Low potassium level - leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination
- Fluid retention - weight gain, feeling short of breath
- Hypoglycemia (low blood sugar) - headache, hunger, sweating, irritability/dizziness/feeling shaky
- Hyperglycemia (high blood sugar) – frequent urination/thirst that continues to be unquenched/extreme feelings of tiredness/blurred vision
For either medication if you experience any unusual or severe symptoms such as muscle cramps/weakness/tremors/fast heartbeat or signs of kidney problems like a change in the amount of urine produced it is important to seek medical help immediately. Remember that everyone's body reacts differently to medications so while some people may experience none others might encounter several side effects.
What are the most common side effects for Novolog?
Novolog, an insulin medication used to control blood sugar levels in people with diabetes, can potentially cause the following side effects:
- Low blood sugar (hypoglycemia)
- Injection site reactions such as redness, swelling or itching
- Weight gain
- Swelling of your hands and feet
- Allergic reactions which may lead to rash or shortness of breath
- Fast heartbeat
- Headache or dizziness
- Muscle pain or weakness
Remember that not everyone will experience these side effects and they are often a trade-off for better glucose control. Always consult your doctor if you have any concerns about potential side effects.
Are there any potential serious side effects for Novolog?
Novolog, like any medication, can cause side effects. While many people experience no or minor side effects, there are instances where more serious reactions may occur:
- Signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue or throat
- Unusual changes in mood or behavior
- Symptoms of heart failure such as shortness of breath that is worse than usual, swelling in your feet or ankles, rapid weight gain
- Severe pain in your upper stomach spreading to your back and vomiting
- Low potassium level with symptoms including leg cramps and constipation
- Vision problems
If you notice these symptoms after taking Novolog it's important to contact a healthcare provider immediately.
Contraindications for Levemir and Novolog?
Both Levemir and Novolog, like all insulin medications, may cause hypoglycemia (low blood sugar) in some individuals. If you notice symptoms of hypoglycemia such as shakiness, dizziness, sweating or confusion, it is important to seek immediate medical attention.
Neither Levemir nor Novolog should be used if you are allergic to any of their ingredients or if you are experiencing an episode of hypoglycemia. Always inform your healthcare provider about the medications and supplements that you're taking; certain drugs can affect blood glucose levels and necessitate adjustments in insulin dosage.
Levemir and Novolog have different durations of action: while Levemir provides a steady level of insulin over 24 hours for maintaining baseline blood sugar control, Novolog acts quickly but has a shorter duration making it more suitable for controlling mealtime spikes in blood sugar. Therefore they are usually prescribed together but never mixed in the same injection.
How much do Levemir and Novolog cost?
For the brand name versions of these drugs:
- The price of a 10ml vial (100units/ml) of Levemir averages around $290, which works out to approximately $9.50 per day if you are using an average dose of about 30 units/day.
- The price for one vial (10ml, 100units/ml) of NovoLog is roughly $300, working out to about $10 per day on an average daily dosage basis.
Thus, if your insulin needs fall within the typical range (i.e., 15 - 45 units/day), then brand-name Levemir tends to be slightly less expensive on a per-day treatment basis than Novolog. However, it's important to understand that cost should not be a primary consideration in determining which diabetes medication is best for you.
Currently there are no generic equivalents available for either Levemir or NovoLog; their prices therefore reflect those typically found at U.S. pharmacies and do not include any potential discounts or insurance coverage that might affect the final cost.
Popularity of Levemir and Novolog
Insulin detemir, also known by the brand name Levemir, was estimated to have been prescribed to about 2.8 million people in the US in 2020. Insulin detemir accounted for just over 12% of long-acting insulin prescriptions in the US. It appears to be a common choice due to its consistent glucose-lowering effect and lower risk of hypoglycemia compared with NPH insulin.
On the other hand, Insulin aspart, commonly known under the brand name Novolog, was prescribed to approximately 5 million people in America during 2020. In terms of rapid-acting insulin prescriptions within the USA, Novolog accounts for roughly around 37%. Over recent years its prevalence has remained steady holding its place as one of top choices for mealtime blood sugar control amongst type 1 and type 2 diabetes patients.
Conclusion
Both Levemir (insulin detemir) and Novolog (insulin aspart) have well-established records of usage in patients with diabetes, and are backed by numerous clinical studies indicating that they effectively control blood glucose levels. In some instances, these insulin types may be used together to manage daily insulin needs; however careful consideration must be given by a physician due to their different mechanisms of action. Levemir is a long-acting insulin primarily utilized to help control your blood sugar throughout the entire day, while Novolog is a rapid-acting insulin designed for use at meal times to combat potential spikes in blood glucose.
Both insulins are available in generic form which could yield significant cost savings particularly for those paying out-of-pocket. Both Levemir and Novolog require an adjustment period meaning that optimal dosage might take time to determine.
The side effect profile is relatively similar between the two insulins with hypoglycemia being the most common adverse reaction. However, weight gain tends to occur less frequently with Levemir than with other basal insulins like Novolog. Patients using either drug should closely monitor their blood glucose levels especially when initiating treatment or adjusting dosages and seek immediate medical attention if they experience symptoms indicative of severe low or high blood sugar.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Chapman, T. M., Noble, S., & Goa, K. L. (2003). Spotlight on Insulin Aspart in Type 1 and 2 Diabetes Mellitus*. Treatments in Endocrinology. Springer Science and Business Media LLC.http://doi.org/10.2165/00024677-200302010-00006
- Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., … Draeger, E. (2003, March 1). Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/diacare.26.3.590
- Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004, April 1). Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. Springer Science and Business Media LLC.http://doi.org/10.1007/s00125-004-1365-z
- Home, P., Bartley, P., Russell-Jones, D., Hanaire-Broutin, H., Heeg, J.-E., Abrams, P., … on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (Steadiness) Study Group. (2004, May 1). Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/diacare.27.5.1081
- Young, J. R., & Mcadam-Marx, C. (2010, January). Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Clinical Medicine Insights: Endocrinology and Diabetes. SAGE Publications.http://doi.org/10.4137/cmed.s5330
- Keating, G. M. (2012, December). Insulin Detemir. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11470200-000000000-00000
- Christiansen, J. S. (2007, September). Insulin aspart: rapid control for postmeal glucose excursions. Expert Review of Endocrinology & Metabolism. Informa UK Limited.http://doi.org/10.1586/17446651.2.5.587
- Gammeltoft, S., Hansen, B. F., Dideriksen, L., Lindholm, A., Schäffer, L., Trüb, T., … Kurtzhals, P. (1999, September). Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opinion on Investigational Drugs. Informa Healthcare.http://doi.org/10.1517/13543784.8.9.1431
- Le Floch, J.-P., Lévy, M., Mosnier-Pudar, H., Nobels, F., Laroche, S., Gonbert, S., … The Assessment of Detemir Administration in a Progressive Treat-to-Target Trial (ADAPT) Study Group. (2009, January 1). Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc08-0332
- Tschritter, O., Schäfer, S. A., Klett, J., Pfäfflin, A., Häring, H. ‐U ., Hennige, A. M., & Fritsche, A. (2009, September 28). Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. Diabetes, Obesity and Metabolism. Wiley.http://doi.org/10.1111/j.1463-1326.2009.01085.x
- De Leeuw, I., Vague, P., Selam, J. ‐L ., Skeie, S., Lang, H., Draeger, E., & Elte, J. W. F. (2004, November 10). Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes, Obesity and Metabolism. Wiley.http://doi.org/10.1111/j.1463-1326.2004.00363.x